---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001900"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:55:42.742654+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)

## Summary
- ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.
- One complete response in combo arm; progressive disease rate 16.2% vs 42.1%.
- Secondary endpoints (PFS, OS, DoR) not yet mature; expected Q4 2025 after 80% event threshold.
- Safety consistent with prior studies; DMC recommended continuation after four reviews.
- BTC affects ~23,000 US patients annually; ~85% lack approved second-line targeted therapy.

## SEC filing metadata
- accession: 0001171843-25-001900
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/0001171843-25-001900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/f8k_040125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001900
- JSON: https://secwatch.observer/filing/0001171843-25-001900.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.